Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Study from Italy Emphasizing Head and Neck Areas - Poll - MDSpire

Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Study from Italy Emphasizing Head and Neck Areas

  • By

  • Luigi Gargiulo

  • Luciano Ibba

  • Matteo Bianco

  • Sara Di Giulio

  • Mario Valenti

  • Gianluca Avallone

  • Martina Zussino

  • Paolo Calzari

  • Angelo Valerio Marzano

  • Antonio Costanzo

  • Silvia Mariel Ferrucci

  • Alessandra Narcisi

  • March 28, 2026

  • 0 min

Share

Original Source(s)

Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Study from Italy Emphasizing Head and Neck Areas

  • by Luigi Gargiulo, Luciano Ibba, Matteo Bianco, Sara Di Giulio, Mario Valenti, Gianluca Avallone, Martina Zussino, Paolo Calzari, Angelo Valerio Marzano, Antonio Costanzo, Silvia Mariel Ferrucci, Alessandra Narcisi

  • March 28, 2026

Related Content

Case Report: Ivarmacitinib in the treatment of refractory primary cutaneous amyloidosis

Summary of Research: Immunogenicity of Dupilumab in Adult and Pediatric Patients with Atopic Dermatitis

Atopic Dermatitis Treatment Targets Defined

Consensus definitions for disease control in atopic dermatitis aim to standardize clinical trial end points and support treat-to-target strategies.